IP Library › Granted Patent US 9,017,693
Granted Patent B2
US 9,017,693 · App. 12/977,672 · Granted Apr 28, 2015

Apoptotically active peptides

Inventors: Mark A. Freyberg (Darmstadt, DE); Peter Friedl (Gross-Umstadt, DE); Dirk Kaiser (Eppertshausen, DE)
Assignee: Cytotools AG
C07K14/4747A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,017,693
App. No.
12/977,672
Granted
Apr 28, 2015
Kind
B2
Abstract

Specific amino acid sequences and peptides and/or peptide mimetics deducted therefrom influencing apoptosis, and the use thereof for the production of pharmaceuticals as diagnostic tools are shown.

Claims (5)

1. Apoptotically active substance comprising a peptide having one of the amino acid sequences selected from the group consisting of M-V-V-Y-F-R (SEQ ID NO: 12), R-A-Y-V-V-A (SEQ ID NO: 13), R-L-Y-V-V-M (SEQ ID NO: 14), R-P-Y-V-V-M (SEQ ID NO: 15), R-S-Y-V-V-M (SEQ ID NO: 16), R-C-Y-V-V-M (SEQ ID NO: 17), m-v-v-y-f-r (D-amino acids) (SEQ ID NO: 18) and m-v-v-y-a-r (D-amino acids) (SEQ ID NO: 19), wherein the peptide induces apoptosis wherein the apoptotically active peptide has less than 15 amino acids.

2. Substance according to claim 1 , which is labeled.

3. A pharmaceutical composition comprising a substance according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

4. Substance according to claim 1 , wherein the peptide is SEQ ID NO: 18.

5. Substance according to claim 1 , wherein the peptide is SEQ ID NO: 19.

Priority Claims (1)
DE 101 63 130 · Dec 20, 2001 · national
Continuity (2)
Division 10499930
Related Publication 20110178000A1 · Jul 21, 2011